Insulin prevents latent skin lesions by inhibiting the generation of advanced glycation end products in streptozotocin-induced diabetic rats

Endocrine Pathology

Volumn 20, Issue 3, 2009, Pages 163-169

  Chen, Xiangfang ^a   Lin, Weidong ^b   Lu, Shuliang ^c   Shi, Yongquan ^a   Zou, Junjie ^a   Liu, Zhimin ^a   Liao, Wanqing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Burns   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Diabetes mellitus; Insulin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HEMOGLOBIN A1C; INSULIN; STREPTOZOCIN; ANTIDIABETIC AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; CELL ORGANELLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DOWN REGULATION; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MALE; MORNING DOSAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKIN DEFECT; STREPTOZOCIN DIABETES; ANIMAL; BIOSYNTHESIS; EXPERIMENTAL DIABETES MELLITUS; MICROVASCULATURE; PATHOLOGY; SKIN; SKIN DISEASE; SPRAGUE DAWLEY RAT; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; VASCULARIZATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INSULIN; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MICROVESSELS; RATS; RATS, SPRAGUE-DAWLEY; SKIN; SKIN DISEASES;

EID: 70449719583     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-009-9084-0     Document Type: Article

References (26)

1. Wertheimer E. Diabetic skin complications: a need for reorganizing the categories of diabetes-associated complications. Israel Med Assoc J 6:287-289, 2004. (Pubitemid 38628338)
2. Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care 24:1019-1022, 2001. doi:10.2337/diacare.24.6.1019.
3. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 3:513-521, 1990. doi:10.2337/diacare.13.5. 513.
4. Bloomgarden ZT. The Diabetic Foot. Diabetes Care 31:372-376, 2008. doi:10.2337/dc08-zb02. (Pubitemid 351213355)
5. Brooks BA, McLennan SV, Twigg SM, Yue DK. Detection and characterisation of microcirculatory abnormalities in the skin of diabetic patients with microvascular complications. Diab Vasc Dis Res 5:30-35, 2008. doi:10.3132/dvdr.2008.006. (Pubitemid 351507343)
6. Jaap AJ, Pym CA, Seamark C, Shore AC, Tooke JE. Microvascular function in type 2 (non-insulin-dependent) diabetes: improved vasodilation after one year of good glycaemic control. Diabetic Med 12:1086-1091, 1995. (Pubitemid 26009950)
7. Cavallini M. Autologous fibroblasts to treat deep and complicated leg ulcers in diabetic patients. Wound Rrepair Regen 15:35-38, 2007. doi:10.1111/j.1524-475X.2006.00182.x. (Pubitemid 46146660)
8. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 9:2654-2659, 2006. doi:10.2337/dc05-2173. (Pubitemid 44912194)
9. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with longterm intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications: DCCT Skin Collagen Ancillary Study Group: Diabetes Control and Complications Trial. Diabetes 48:870-880, 1999. doi:10.2337/ diabetes.48.4.870.
10. Tabor CA, Parlette EC. Cutaneous manifestations of diabetes. Signs of poor glycemic control or new-onset disease. J Postgra Med 119:38-44, 2006.
11. Kurcer Z, Parlakpinar H, Vardi N, Tasdemir S, Iraz M, Fadillioglu E, Baba F, Gül M. Protective effects of chronic melatonin treatment against renal ischemia/reperfusion injury in streptozotocin-induced diabetic rats. Exp Clin Endocr Diab 115:365-371, 2007. doi:10. 1055/s-2007-971056.
12. Kun Hwang, Dae Joong Kim, Se Ho Hwang. Thickness of Korean upper eyelid skin at different levels. J Craniofac Surg 17(1):54-56, 2006. doi:10.1097/01.scs.0000188347.06365.a0. (Pubitemid 44383847)
13. Bannai C, Yamazaki M, Matsushima Y, Kunika K, Itakura M, Okuda Y, Yamashita K. Amelioration of dermal lesions in streptozotocin-induced diabetic rats by aminoguanidine. Diabetes Res 20:87-95, 1992.
14. Sajithlal GB, Chithra P, Chandrakasan G. Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Biochem Pharmacol 56:1607-14, 1998. doi:10.1016/S0006- 2952(98)00237-238
15. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pr 67: 3-21, 2005. doi:10.1016/j.diabres.2004. 09.004. (Pubitemid 40037725)
16. Jelinek JE. The skin in diabetes. Diabetic Med 10: 201-213, 1993.
17. Mulder DJ, Water TV, Lutgers HL, Graaff R, Gans RO, Zijlstra F, Smit AJ. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 8:523-535, 2006. doi:10.1089/dia.2006.8. 523. (Pubitemid 44946877)
18. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 9:233-245, 2007. doi:10.1111/j.1463-1326.2006.00595.x (Pubitemid 46502041)
19. Sajithlal GB, Chithra P, Chandrakasan G. Advanced glycation end products induce crosslinking of collagen in vitro. Biochim Biophys Acta 1407:215-224, 1998.
20. Hammes HP, Weiss A, Hess S, Araki N, Horiuchi S, Brownlee M, Preissner KT. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest 75:325-338, 1996.
21. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfeld RG. Connective tissue growth factor/IGFbinding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 143:1260-1269, 2002. doi:10.1210/en. 143.4.1260 (Pubitemid 34274355)
22. Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, Motoyama K, Mori K, Fukumoto S, Shioi A, Shimogaito N, Takeuchi M, Yamamoto Y, Yonekura H, Yamamoto H, Nishizawa Y. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 55:2245-2255, 2006. doi:10.2337/db05-1375. (Pubitemid 44743621)
23. Bitar MS. Glucocorticoid dynamics and impaired wound healing in diabetes mellitus. Am J Pathol 152: 547-554, 1998.
24. Galkowska H, Wojewodzka U, Olszewski WL. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen 14:558-565, 2006. doi:10.1111/j.1743-6109. 2006.00155.x. (Pubitemid 44470072)
25. Ahmed I, Goldstein B. Diabetes mellitus. Clin Dermatol 24:237-246, 2006. doi:10.1016/j.clindermatol.2006.04.009 (Pubitemid 43977877)
26. Spravchikov N, Sizyakov G, Gartsbein M, Accili D, Tennenbaum T, Wertheimer E. Glucose effects on skin keratinocytes: implications for diabetes skin complications. Diabetes 50: 1627-1635, 2001. doi:10.2337/diabetes.50.7.1627